A Monoclonal Antibody Assessment of the Beta-Microseminoprotein Expression in Prostatic Carcinoma as a Prognostic Indicator
スポンサーリンク
概要
- 論文の詳細を見る
Using a newly generated monoclonal antibody for human beta-microseminoprotein(β-MSP), which is among the proteins secreted by the prostatic gland, this study has investigated whetherβ-MSP immunoreactivity can be a prognostic indicator of prostatic carcinama. To accomplish this,β-MSP immunoreactivity was. evaluated in needle biopsy specimens of 116 patients with prostatic carcinoma. Results have indicated a higher cancer-specific survival rate in patients with a greater response to β-MSP immunostaining (p = 0.04). Further, a multivariate analysis of possible prognostic factors, i. e., the patient age, the clinical stage, the histological grade (Gleason's score), the serum PAP content, the β-MSP immunoreactivity, and the initial treatment received, has confirmed that β-MSP immunoreactivity is a significant prognostic indicator of prostatic carcinoma (p = 0.05). Thus, the use of a monoclonal antibody to evaluate β-MSP immunoreactivity has been found to be a useful indicator for assessing the activity of prostatic carcinoma.
- 長崎大学の論文